The study of urotensi-II in type 2 diabetes mellitus patients with severe obstructive sleep apnea syndrome

Objective To evaluate the clinical effects and significance of serum Urotensin Ⅱ(Ⅶ) in type 2 diabetes mellitus(T2DM)patients with severe obstructive sleep apnea syndrome(OSAS).Methods Total 90 patients with type 2 diabetes mellitus patients and severe OSAS(trial group) and 30 normal people(control group) were enrolled.The contents of serum Ⅶ were detected with radioimmunoassay,and saturation of arterial blood oxygen(SpO2) and the levers of fasting glucose were detected.Results The levels of serum UII in the trial group(mild,moderate,severe) and in control group were(6.8±0.9) pg/ml,(7.9±1.8) pg/ml,(9.2±1.1) pg/ml and(7.1±1.0) pg/ml,and the differences in the four groups were significant(P0.05);SpO2 in trial group(mild,moderate,severe) and control group were(86.4±2.9)%,(82.2±3.8)%,(60.8±15.2)% and(94.3±5.6)%,there were significant different in trial group and control group(P0.05);the fasting glucose(FPG) in trial group(mild,moderate,severe) and control group were(7.2±1.1) mmol/l,(8.5±2.1) mmol/L,(11.6±1.4) mmol/L and(4.5±0.7) mmol/L,the different in trial group and control group were significant(P0.05).The levels of serum UII,SpO2 and FPG were significant different in two trial groups(P0.05).Conclusion Increase of Urotensin Ⅱ may be an important factor for occurrence and development of T2DM patients with OSAS.